Literature DB >> 27072269

Abberent expression of oncogenic and tumor-suppressive microRNAs and their target genes in human adenocarcinoma alveolar basal epithelial cells.

Elham Tafsiri, Mojtaba Darbouy, Mohammad Behgam Shadmehr, William C Cho, Morteza Karimipoor1.   

Abstract

CONTEXT: Lung cancer is one of the most serious types of cancer that often diagnosed at advanced stage. MicroRNAs (miRNAs) are small non-coding molecules which silence gene expression of target gene (s) at posttranscriptional level. They are key regulators of cell cycle, apoptosis, anti-cancer drug responsiveness and metastasis. AIMS: Identification of the differential expression level of miR-15a/16, miR-21, miR-34a, miR-126, miR-128 and miR-210 in A549 cell line versus normal tissues and their correlation with selected corresponding target genes.
MATERIALS AND METHODS: A549 cell line was cultured in F-12K medium and miRNA was extracted from normal tissues (2-3 cm adjacent to tumor tissue) and A549 cell line. cDNA was synthesized with specific stem-loop primers for each miRNA, while OligodT primer was used for target genes cDNA synthesis. Real-time quantitative polymerase chain reaction. (RT-qPCR) was used to analyze the expression pattern of miRNAs and target genes in A549 and normal non-small cell lung carcinoma. (NSCLC) tissues.
RESULTS: miR-15a/16, miR-34a, miR-126 and miR-128 were down-regulated significantly. (>2-fold change), while miR-21 and miR.210 were up-regulated in A549. Bcl-2 as miR-34a target gene was down-regulated while Hif-1α and Akt-3 were up-regulated that might be miR-210 and miR-34a target genes, respectively.
CONCLUSION: The significant differential expression level of these miRNAs made them as candidate biomarkers in NSCLC tumor tissues of patients. Perhaps Bcl-2 down-regulation and Akt-3 up-regulation can be linked with survival signals in A549 cell line. We can conclude that Bcl-2 and Akt-3 might be therapeutic targets to inhibit cell proliferation in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27072269     DOI: 10.4103/0973-1482.148673

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  5 in total

Review 1.  Reciprocal regulations between miRNAs and HIF-1α in human cancers.

Authors:  Wanli Yang; Jiaojiao Ma; Wei Zhou; Bo Cao; Xin Zhou; Hongwei Zhang; Qingchuan Zhao; Liu Hong; Daiming Fan
Journal:  Cell Mol Life Sci       Date:  2018-10-13       Impact factor: 9.261

2.  Activation of p53/miR-34a Tumor Suppressor Axis by Chinese Herbal Formula JP-1 in A549 Lung Adenocarcinoma Cells.

Authors:  Chih-Jung Yao; Jyh-Ming Chow; Pei-Chun Lin; Tsai-Shu Hu; Hui-Ching Kuo; Jhy-Shrian Huang; Kuan-Jen Bai; Gi-Ming Lai
Journal:  Evid Based Complement Alternat Med       Date:  2016-12-18       Impact factor: 2.629

3.  Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets.

Authors:  Mehrdad Pazhouhandeh; Fatemeh Samiee; Tahereh Boniadi; Abbas Fadaei Khedmat; Ensieh Vahedi; Mahsa Mirdamadi; Naseh Sigari; Seyed Davar Siadat; Farzam Vaziri; Abolfazl Fateh; Faezeh Ajorloo; Elham Tafsiri; Mostafa Ghanei; Fereidoun Mahboudi; Fatemeh Rahimi Jamnani
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

4.  A Rare Report of Lung Metastasis of the Common Non-Melanotic Skin Cancer.

Authors:  Mohsen Shafiepour; Arda Kiani; Kimia Taghavi; Sharareh Seifi; Mitra Sadat Rezaie; Seyed Mohammad Reza Hashemian; Atefeh Abedini
Journal:  Tanaffos       Date:  2018-01

5.  The prognostic value of miR-126 expression in non-small-cell lung cancer: a meta-analysis.

Authors:  Wen Zheng; Ya Zhou; Jia Lu; Hualin Xu; Liangyu Lei; Chao Chen; Juanjuan Zhao; Lin Xu
Journal:  Cancer Cell Int       Date:  2017-07-14       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.